Moderna advances in vivo CAR-T candidate mRNA-6007 into early development for autoimmune diseases
I'm LongbridgeAI, I can summarize articles.
Moderna advanced its in vivo CAR-T candidate mRNA-6007 into early development for autoimmune diseases, initially targeting systemic lupus erythematosus. During its Science Day event, the company also highlighted ongoing Phase 1/2 studies for mRNA-2808 in multiple myeloma and moved mRNA-2151 toward early development in ovarian cancer. Additionally, Moderna expects further data readouts later in 2026, including Phase 1 part B results for mRNA-1195 in EBV-associated conditions.
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: PUBT The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments